Trials / Completed
CompletedNCT01621672
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
Myeloma Cure Project: Prospective, Randomized Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Who Have Completed 3 Years of VTD/TD or VTD or VRD Maintenance on Total Therapy 3 (TT3) Trials 2003-33 and 2006-66
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- University of Arkansas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine in a phase II trial, whether further maintenance therapy with Revlimid can extend the duration of progression-free survival and the duration of complete or near complete response compared to no further therapy beyond the TT3 protocol-prescribed 3 years of maintenance with 1 year of VTD plus 2 years with TD, 3 years with VTD (2003-33) or VRD (2006-66).
Detailed description
Determine the associated toxicities in qualitative and quantitative terms using NCI CTCAE(NCI common terminology for adverse events)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Revlimid | 10 mg/day in the morning same time each day |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2012-06-18
- Last updated
- 2015-10-19
- Results posted
- 2015-09-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01621672. Inclusion in this directory is not an endorsement.